Transplant News and Research

RSS

Researchers develop new method for individually adapted implants

Researchers at Mid Sweden University, together with Professor Jan Hirsch and Consultant Per Dérand, oral & maxillofacial surgeons at Uppsala University Hospital and Mälarsjukhuset Hospital, respectively, have developed an entirely new method for individually adapted implants.

14 Dec 2009

MHI launches new research program in heart failure

The Montreal Heart Institute (MHI) and its Foundation (MHIF) launched today the Carolyn and Richard J. Renaud Research Chair in Heart Failure, the first of its kind in Québec.

14 Dec 2009

Trial date set for patent litigation in the U.S. District Court for the District of Delaware

Cubist Pharmaceuticals, Inc. today announced that a trial date has been set for patent litigation in the U.S. District Court for the District of Delaware against Teva Parenteral Medicines, Inc. (TPM), Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. alleging infringement of Cubist’s US Patent Nos. 6,468,967 and 6,852,689, which expire on September 24, 2019, and US Patent No. RE39,071, which expires on June 15, 2016.

14 Dec 2009

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

Cubist Pharmaceuticals, Inc. a leading acute care therapeutics company, announced today the signing of a definitive agreement under which Cubist has agreed to acquire privately held Calixa Therapeutics Inc., a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens.

14 Dec 2009

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

A modified blood adult stem-cell transplant regimen has effectively reversed sickle cell disease in 9 of 10 adults who had been severely affected by the disease, according to results of a National Institutes of Health study in the Dec. 10 issue of the New England Journal of Medicine.

13 Dec 2009

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML).

11 Dec 2009

Zevalin clinical data presented at 2009 ASH meeting

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN (ibritumomab tiuxetan) was presented at the 51st Annual Meeting of the American Society of Hematology (ASH), which was held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

11 Dec 2009

Cell transplants may yield new therapies for dementia patients

Nerve cells transplanted into brain-damaged rats helped them to fully recover their ability to learn and remember, probably by promoting nurturing, protective growth factors, according to a new study.

10 Dec 2009

Preliminary study shows 'mini' stem cell transplantation may safely reverse severe sickle cell disease

Results of a preliminary study by scientists at the National Institutes of Health and Johns Hopkins show that "mini" stem cell transplantation may safely reverse severe sickle cell disease in adults.

9 Dec 2009

Pacific Beach BioSciences signs licensing agreement with major pharmaceutical company

Pacific Beach BioSciences, Inc. today reported that it has granted non-exclusive rights to a large pharmaceutical company for the use of one of its anti-fungal compounds required for the manufacturing of a clinical stage product.

9 Dec 2009

CORD:USE Cord Blood Bank awarded contract to supply blood units for the NCBI

CORD:USE Cord Blood Bank is proud to announce that the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services has awarded CORD:USE Cord Blood Bank a three-year, multi-million dollar contract to expand the supply of cord blood units for the National Cord Blood Inventory (NCBI).

9 Dec 2009

AHS annual meeting focuses on myeloma, says IMF

The International Myeloma Foundation (IMF)—supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians— says a large number of abstracts – nearly a quarter of the presentations submitted this year to the annual meeting of the American Society of Hematology (ASH) were for myeloma, with one being presented at the prestigious plenary session.

9 Dec 2009

Human blood stem cells can be engineered to kill HIV and other chronic viral diseases

Researchers from the UCLA AIDS Institute and colleagues have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells - a process that potentially could be used against a range of chronic viral diseases.

9 Dec 2009

Memgen announces positive clinical data of ISF35 with chemotherapy

Memgen announced today that positive data evaluating its active cellular immunotherapy product, ISF35, in combination with chemotherapy in resistant chronic lymphocytic leukemia (CLL) were presented December 7 during the 51st Annual Meeting of the American Society of Hematology (Abstract #376).

9 Dec 2009

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Genzyme Corporation announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow.

9 Dec 2009

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company’s oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.

8 Dec 2009

$Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma$

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced results from an ongoing Phase 2 study, known as the 004 study, of the company's lead proteasome inhibitor, carfilzomib.

8 Dec 2009

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in its Phase I/IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in combination with standard antiviral treatment and vaccination in HBeAg-negative chronic hepatitis B-infected (HBV) patients.

8 Dec 2009

Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML

Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.

8 Dec 2009

Patients with recurrent shoulder dislocations may benefit from new surgical technique

The shoulder is the most commonly dislocated joint in the human body, occurring most often in young, athletic people. New research from the University of Michigan Health System shows patients who have recurrent shoulder dislocations may benefit from surgical reconstruction using cadaver bone and cartilage to essentially 'sculpt' a new shoulder.

8 Dec 2009

Transplant News and Research

Researchers develop new method for individually adapted implants

MHI launches new research program in heart failure

Trial date set for patent litigation in the U.S. District Court for the District of Delaware

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Zevalin clinical data presented at 2009 ASH meeting

Cell transplants may yield new therapies for dementia patients

Preliminary study shows 'mini' stem cell transplantation may safely reverse severe sickle cell disease

Pacific Beach BioSciences signs licensing agreement with major pharmaceutical company

CORD:USE Cord Blood Bank awarded contract to supply blood units for the NCBI

AHS annual meeting focuses on myeloma, says IMF

Human blood stem cells can be engineered to kill HIV and other chronic viral diseases

Memgen announces positive clinical data of ISF35 with chemotherapy

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML

Patients with recurrent shoulder dislocations may benefit from new surgical technique

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News